Fulfilling your ablation obsession - ECIO 2025 Rotterdam overview
2025 is in full swing, and we are happy to publish our sneak preview highlighting everything that ECIO in Rotterdam has to offer regarding ablation. Spoiler alert - we will again be showing never-before seen software features (AKA CAS-One IR version 4.3)!
Back by popular demand are the highlights for those obsessed with percutaneous tumor ablation. Below are some CASCINATION highlights as the "can't-miss" sessions that you should put on your calendar.
Before we highlight the ablation-only specifics, one topic caught our eye. CF 323 The future of IO - We have to build it.
This is a very well-titled session, and we at CASCINATION feel it is the most important session to attend, as there is a lot at stake. Mark your calendar, Tuesday, April 15th, 10:30-12:00!
Now, back to ablation.
First of all - we invite you to come by the CASCINATION booth and see two new things:
To start, there is our AI Challenge. this is the 3rd iteration of the challenge with over 100 participants from 14 countries so far. In this iteration, where participants can challenge themselves to "eyeball" an ablation zone to see of they are satisfied with the treatment, and then make a plan to re-treat - and see how similar it is to the CAS-One IR "reablation" feature
Secondly, a sneak-preview of CAS-One IR version 4.3. We will have a demonstration version of the brand-new, in-development software that has one MAJOR change to it! Come by to see it.
If you are new to learning about Quality Ablation with CAS-One IR, a short video can be found here
Now, for the scientific congress highlights.
In 2023 at Stockholm, there were 6 abstracts featuring CAS-One IR. 2024 in Palma had 7. This year there are 10 accepted abstracts that use or focus on CAS-One IR.
It is very challenging to make a "short list" of sessions, but below are the ones that made our cut - make some calendar reminders or use the ECIO app to make sure you don't miss it!
ECIO 2025 Program overview
Sunday April 13th
CF 111 - HCC management from 2020 to 2025: the revolution in...
8:30-10:00 Auditorium 1 - Moderators: P. Pereira, M. Kudo
111.3 ...ablation - M. Burgmans
CF 121 - The usual suspects: IO management of osseous metastases
10:30-12:00 Auditorium 1 - Moderators: R. Cazzato, S. Tutton
121.3 Thermal ablation for osseous metastases: optimal lesion and modality selection - A. Kelekis
121.6 Bringing it all together: optimal modality combination algorithm for osseous metastases - S. Tutton
CF 122 Ethical, practical, and collaborative uses of AI in interventional oncology
10:30-12:00 Auditorium 2 - Moderators: F. Gomez Munoz, B. Meyer
122.3 Learning from AI successes: charting the path forward - B. Odisio
CF 123 - Understanding the "oligo" patient: progression, persistence, and resistance
10:30-12:00 Auditorium 3 - Moderators: D. Arnold, M. Meijerink
123.5 An update in local ablative treatments in oligometastatic disease - S. Van Der Lei
TF 142 - How to perform a safe and effective procedure
15:00-16:30 Auditorium 2 - Moderators: B. Guiu, P. Haage
142.1 Catheter-guided liver tumor ablation - M. Smits
142.2 Combined treatment of HCC: TACE and ablation - T. Jakobs
142.5 Electrochemotherapy for liver tumors - F. Orsi
CF143 - Meet the PI: upcoming research
15:00-16:30 Auditorium 3 - Moderators: R. Cazzato, P. Reimer
143.3 CRYODESMO 2 - R. Cazzato
CF152 - Mastering local treatment of metastatic colorectal cancer
17:00-18:30 Auditorium 2 - Moderators: J. Durand Labrunie, S. Stattner
152.2 Thermal ablation vs. surgical resection for small-size CRLM: the COLLISION trial aftermath - M. Meijerink
152.3 Percutaneous ablation vs. laparoscopic ablation CRLM - H. Pommergaard
152.5 Ablation of colorectal pulmonary metastases - J. Palussiere
152.6 Systemic and ablative treatment: when is the best timing - D. Arnold
Monday April 14th
TB 211 - Tumor board: metastatic colorectal cancer
8:30-10:00 Auditorium 1 - Moderators: C. Sofocleous, U. Cillo
211.1 The ESMO treatment algorithm and treatment perspective 2025 - D. Arnold
211.3 Update on local ablative modalities - B. Odisio
CF 242 - Kidney cancer management
15:00-16:30 Auditorium 2 - Moderators: X. Buy, T. Wah
242.1 Common pitfalls to avoid in percutaneous ablation - L. Klompenhouwer
254.2 Stereotactic guidance, ablation planning, ablation verification in kidney cancer - R. Garcia Marcos
241.3 Kidney tumour ablation: RCT vs real-world evidence - D. Breen
CF 252 - Planning IO treatments and evaluating the results
17:00-18:30 Auditorium 2 - Moderators: P. Pereira, A. Adam
252.2 How to use functional imaging or biomarkers to improve the outcomes of tumor ablation - C. Sofocleous
252.3 The challenges of stereotactic thermal ablation and how technology can overcome them - G. Laimer
Tuesday April 15th
CF311 - HCC Management from 2025 to 2030 - get ready for the beta generation
8:30-10:00 Auditorium 1 - Moderators: M. Ronot, V. Mazzaferro
311.2 The next generation of devices - R. Iezzi
311.5 The role of biopsy for treatment decision - V. Paradis
CF312 - MSK roads less travelled
8:30-10:00 Auditorium 2 - Moderators: A. Ryan, J. Jennings
312.1 The role of fusion imaging, navigation systems, and robotics in MSK interventional oncology - D. Filipiadis
312.4 Sarcomas: is there a role for percutaneous ablation - M. Callstrom
312.5 Thermal ablation of desmoid tumors: evolution since CRYO-DESMO - A. Gangi
SP 313 - IO from neck to bone
8:30-10:00 Auditorium 3 - Moderators: L. Solbiati, E de Kerviler
313.3 Cryoablation for treatment of peripheral lung metastases from colorectal cancer: a bicenter retrospective study - G. Piana
313.6 Outcomes of thermoprotective techniques in image-guided ablation of musculoskeletal tumors - J. Jennings
TB 321 - Tumor board: renal cancer
10:30-12:00 Auditorium 1 - Moderators D. Filippiadis, X. Buy
321.1 When to resect ablatable tumors - P. Zondervan
321.2 When to ablate resectable tumors - X. Buy
CF 323 The future of IO - We have to build it
10:30 - 12:00 Auditorium 3 - Moderators: T. Helmberger, G. Carrafiello,
323.2 AI in IO: navigating medical responsibilty - G. Carafiello,
323.3 Is IO prepared for the future? The US perspective - R. Lewandowski
323.4 Is IO prepared for the future? The EU perspective - P. Pereira
323.5 The future generation perspective 1 - P. Varela Alvarez
323.6 The future generation perspective 2 - E. Efthymiou
TF 342 How to perform a safe and effective procedure: a step-by-step approach
15:00-16:30 Auditorium 2 - Moderators: M. Krokidis, A. Gangi
342.1 IRE of pancreatic cancer - G. Narayanan
342.2 Ablation of lung tumors - M. Calandri
342.3 Tumor cryoablation in the small child - A. Barnacle
342.4 Ablation of kidney cancer - S. Shen
342.5 Ablation of adrenal tumors - G. Tsoumakidou
TF 351 Tumor board: lung cancer
17:00-18:30 Auditorium 1 - Moderators: R. Suh, L Tselikas
351.3 Limitations of the use of thermal ablation on lung tumors - R. Grasso
SP 352 IO in liver tumors: from established to new approaches
17:00-18:30 Auditorium 2 - Moderators: M. Calandri, G. Narayanan
352.3 Thermal ablation versus surgical resection of small-size colorectal liver metastases: an international, randomized, controlled, phase III non-inferiority trial (COLLISION) - S. Van Der Lei
352.4 Long-term results of MWA in the treatment of very-early and early-stage HCC: the MARATHON study - G. Candita
352.5 Percutaneous cryoablation versus microwave ablation of hepatocellular carcinoma: a comparative study of safety and oncologic outcomes - D. Chlorogiannis
352.6 Efficacy, safety, and long-term oncological outcomes of irreversible electroporation for hepatocellular carcinoma BCLC 0, A and B: a bi-institutional retrospective study - O. Sutter
Wednesday April 16th
TB 411 - Tumor board: HCC
8:30-10:00 - Auditorium 1 - Moderators M. Ronot, D. Pinato
411.2 Modern approaches to IO treatments for HCC - I. Bargellini
Good luck trying to prioritize all of these exciting sessions! We will see you there.